Distek Awarded U.S. Patent 8,903,673
News Feb 24, 2015
Distek, Inc. has been awarded U.S. Patent 8,903,673 for their modularity design and the individual position software control.
Distek’s patented, self-contained, modularity design is configurable for up to 8 positions when in use on the symphony 7100 “Bathless” Dissolution Instrument and 6 positions when in use on thesensIR 3200 “Bathless” Disintegrator. This modularity design allows users unprecedented ease and scalability.
“Distek is excited to have been awarded this patent which exemplifies our commitment to providing technically innovative products offering valuable feature benefits to our customer base,” says Jeff Brinker, President, Distek, Inc.
Brinker continued, “This patent in particular allows our customers a great deal of flexibility in the symphony 7100 and sensIR 3200 platforms in its modularity both mechanically as well as in the user interface design.”
Kidney Cancer Driver Could Lead to New Treatment StrategyNews
Scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change can lead to an overabundance of blood vessels, which help feed nutrients to the tumors. Their latest finding shows a potential new cancer-driving pathway.READ MORE
Targeting Headaches and Tumors with Nano-SubmarinesNews
Scientists have developed a new method to enable miniature drug-filled nanocarriers to dock on to immune cells, which in turn attack tumors. In the future, this may lead to targeted treatment that can largely eliminate damage to healthy tissue.READ MORE
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE